These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23101788)

  • 1. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients.
    Gungor O; Kismali E; Sisman AR; Kircelli F; Carrero JJ; Tatar E; Asci G; Toz H
    Ren Fail; 2013; 35(1):77-81. PubMed ID: 23101788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients?
    Gungor O; Kircelli F; Asci G; Carrero JJ; Tatar E; Demirci MS; Ozbek SS; Ceylan N; Toz H; Ozkahya M; Ok E
    J Nephrol; 2013; 26(1):136-43. PubMed ID: 22505251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.
    Turan MN; Kircelli F; Yaprak M; Sisman AR; Gungor O; Bayraktaroglu S; Ozkahya M; Asci G; Floege J; Ok E
    Int Urol Nephrol; 2016 Apr; 48(4):609-17. PubMed ID: 26865177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
    J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients.
    Balci M; Kirkpantur A; Gulbay M; Gurbuz OA
    Hemodial Int; 2010 Oct; 14(4):425-32. PubMed ID: 20955275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.
    Fernández-Laso V; Sastre C; Valdivielso JM; Fernández E; Martín-Ventura JL; Egido J; Blanco-Colio LM
    Atherosclerosis; 2015 Apr; 239(2):358-63. PubMed ID: 25681674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse Relationship between Plasma Tumor Necrosis Factor-Like Weak Inducer of Apoptosis and Carotid Intima-Media Thickness among Patients Undergoing Hemodialysis and Peritoneal Dialysis.
    Shi X; Qiu B; Shen H; Feng S; Fu J
    Cardiorenal Med; 2020; 10(3):137-144. PubMed ID: 32126565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
    Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The associations between serum paraoxonase 1 activity and carotid atherosclerosis in renal transplant patients.
    Gungor O; Kismali E; Sisman AR; Kircelli F; Asci G; Topal K; Sipahi S; Tuncel P; Ozkahya M; Toz H
    Clin Nephrol; 2013 Sep; 80(3):198-202. PubMed ID: 23547806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast Growth Factor-23 and Carotid Artery Intima Media Thickness in Chronic Kidney Disease.
    Yilmaz G; Ustundag S; Temizoz O; Sut N; Demir M; Ermis V; Sevinc C; Ustundag A
    Clin Lab; 2015; 61(8):1061-70. PubMed ID: 26427152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
    Moreno JA; Muñoz-García B; Martín-Ventura JL; Madrigal-Matute J; Orbe J; Páramo JA; Ortega L; Egido J; Blanco-Colio LM
    Atherosclerosis; 2009 Nov; 207(1):103-10. PubMed ID: 19473660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation.
    Yilmaz MI; Sonmez A; Saglam M; Cayci T; Kilic S; Unal HU; Karaman M; Cetinkaya H; Eyileten T; Gok M; Oguz Y; Vural A; Mallamaci F; Zoccali C
    Clin J Am Soc Nephrol; 2015 Mar; 10(3):471-9. PubMed ID: 25542907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients.
    Turkmen K; Tonbul HZ; Erdur FM; Toker A; Biyik Z; Ozbiner H; Gaipov A; Gul EE; Kayrak M; Solak Y; Ozbek O; Turk S; Covic A
    BMC Nephrol; 2013 Jul; 14():144. PubMed ID: 23849432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association of Fibroblast Growth Factor 23 with Arterial Stiffness and Atherosclerosis in Patients with Autosomal Dominant Polycystic Kidney Disease.
    Coban M; Inci A; Yılmaz U; Asilturk E
    Kidney Blood Press Res; 2018; 43(4):1160-1173. PubMed ID: 30064143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors.
    Chow WS; Xu A; Woo YC; Tso AW; Cheung SC; Fong CH; Tse HF; Chau MT; Cheung BM; Lam KS
    Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2454-9. PubMed ID: 23887638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations Among Cardio-Ankle Vascular Index, Carotid Intima-Media Thickness, and Fibroblast Growth Factor-21 Levels in Kidney Transplant Patients.
    Trakarnvanich T; Prommool S; Kurathong S; Teepprasan T; Wang Y
    Transplant Proc; 2017 Oct; 49(8):1791-1796. PubMed ID: 28923627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
    Rusu CC; Racasan S; Kacso IM; Ghervan L; Moldovan D; Potra A; Patiu IM; Bondor C; Caprioara MG
    Int Urol Nephrol; 2015 Dec; 47(12):2023-30. PubMed ID: 26433887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients.
    Kurnatowska I; Grzelak P; Stefańczyk L; Nowicki M
    Nephrology (Carlton); 2010 Mar; 15(2):184-9. PubMed ID: 20470277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.
    Fernández-Laso V; Méndez-Barbero N; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Atherosclerosis; 2017 May; 260():130-137. PubMed ID: 28390291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
    Yilmaz MI; Sonmez A; Ortiz A; Saglam M; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Egido J; Altun B; Yenicesu M; Blanco-Colio LM; Carrero JJ
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):785-92. PubMed ID: 21330486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.